Currently,drug resistance of anti-cancer therapy has become the main cause of low survival rate and poor prognosis.Full understanding of drug resistance mechanisms is an urgent request for further development of anti-...Currently,drug resistance of anti-cancer therapy has become the main cause of low survival rate and poor prognosis.Full understanding of drug resistance mechanisms is an urgent request for further development of anti-cancer therapy and improve-ment of prognosis.Here we present our N-glycoproteomics study of putative N-glycoprotein biomarkers of drug resistance in doxorubicin resistance breast cancer cell line michigan cancer foundation-7(MCF-7/ADR)relative to parental michigan cancer foundation-7(MCF-7)cells.Intact N-glycopeptides(IDs)from MCF-7/ADR and MCF-7 cells were enriched with zwitterionic hydrophilic interaction liquid chromatography(ZIC-HILIC),labeled with stable isotopic diethylation(SIDE),and analyzed with C18-RPLC-MS/MS(HCD with stepped normalized collision energies);these IDs were identified with database search engine GPSeeker,and the differentially expressed intact N-glycopeptides(DEGPs)were quantified with GPSeekerQuan.With target-decoy searches and control of spectrum-level FDR≤1%,322 intact N-glycopeptides were identified;these intact N-glycopeptides come from the combination of 249 unique peptide backbones(corresponding to 234 intact N-glycoproteins)and 90 monosaccharide compositions(corresponding to 248 putative N-glycosites).The sequence structures of 165 IDs were confirmed with structure-diagnostic fragment ions.With the criteria of observation at least twice among the three technical replicates,≥1.5-fold change and p value<0.05,20 DEGPs were quantified,where five of them were up-regulated and 15 of them were down-regulated;the corresponding intact N-glycoproteins as putative markers of drug resistance were discussed.展开更多
MiR-142-3p has been reported to act as a tumor suppressor in breast cancer.However,the regulatory effect of miR-142-3p on drug resistance of breast cancer cells and its underlying mechanism remain unknown.Here,we foun...MiR-142-3p has been reported to act as a tumor suppressor in breast cancer.However,the regulatory effect of miR-142-3p on drug resistance of breast cancer cells and its underlying mechanism remain unknown.Here,we found that miR-142-3p was significantly downregulated in the doxorubicin(DOX)-resistant MCF-7 cell line(MCF-7/DOX).MiR-142-3p overexpression increased DOX sensitivity and enhanced DOXinduced apoptosis in breast cancer cells.High-mobility group box 1(HMGB1)is a direct functional target of miR-142-3p in breast cancer cells and miR-142-3p negatively regulated HMGB1 expression.Moreover,overexpres sion of HMGB1 dramatically reversed the promotion of apoptosis and inhibition of autophagy mediated by miR-142-3p up-regulation.In conclusion,miR-142-3p overexpression may inhibit autophagy and promote the drug sensitivity of breast cancer cells to DOX by targeting HMGB 1.The miR-142-3 p/HMGB1 axis might be a novel target to regulate the drug resistance of breast cancer patients.展开更多
基金supported by National Natural Science Foundation of China(21775110,22074105)Shanghai Science and Technology Commission(14DZ2261100).
文摘Currently,drug resistance of anti-cancer therapy has become the main cause of low survival rate and poor prognosis.Full understanding of drug resistance mechanisms is an urgent request for further development of anti-cancer therapy and improve-ment of prognosis.Here we present our N-glycoproteomics study of putative N-glycoprotein biomarkers of drug resistance in doxorubicin resistance breast cancer cell line michigan cancer foundation-7(MCF-7/ADR)relative to parental michigan cancer foundation-7(MCF-7)cells.Intact N-glycopeptides(IDs)from MCF-7/ADR and MCF-7 cells were enriched with zwitterionic hydrophilic interaction liquid chromatography(ZIC-HILIC),labeled with stable isotopic diethylation(SIDE),and analyzed with C18-RPLC-MS/MS(HCD with stepped normalized collision energies);these IDs were identified with database search engine GPSeeker,and the differentially expressed intact N-glycopeptides(DEGPs)were quantified with GPSeekerQuan.With target-decoy searches and control of spectrum-level FDR≤1%,322 intact N-glycopeptides were identified;these intact N-glycopeptides come from the combination of 249 unique peptide backbones(corresponding to 234 intact N-glycoproteins)and 90 monosaccharide compositions(corresponding to 248 putative N-glycosites).The sequence structures of 165 IDs were confirmed with structure-diagnostic fragment ions.With the criteria of observation at least twice among the three technical replicates,≥1.5-fold change and p value<0.05,20 DEGPs were quantified,where five of them were up-regulated and 15 of them were down-regulated;the corresponding intact N-glycoproteins as putative markers of drug resistance were discussed.
基金the financial support by National Natural Science Foundation of China(Nos.81330007 and U1601227)the Science and Technology Programs of Guangdong Province(Nos.2014A050503047 and 2015B020225006,China)National Natural Science Foundation of China(81700382)
文摘MiR-142-3p has been reported to act as a tumor suppressor in breast cancer.However,the regulatory effect of miR-142-3p on drug resistance of breast cancer cells and its underlying mechanism remain unknown.Here,we found that miR-142-3p was significantly downregulated in the doxorubicin(DOX)-resistant MCF-7 cell line(MCF-7/DOX).MiR-142-3p overexpression increased DOX sensitivity and enhanced DOXinduced apoptosis in breast cancer cells.High-mobility group box 1(HMGB1)is a direct functional target of miR-142-3p in breast cancer cells and miR-142-3p negatively regulated HMGB1 expression.Moreover,overexpres sion of HMGB1 dramatically reversed the promotion of apoptosis and inhibition of autophagy mediated by miR-142-3p up-regulation.In conclusion,miR-142-3p overexpression may inhibit autophagy and promote the drug sensitivity of breast cancer cells to DOX by targeting HMGB 1.The miR-142-3 p/HMGB1 axis might be a novel target to regulate the drug resistance of breast cancer patients.
